Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pucotenlimab + nab-paclitaxel + tegafur + carboplatin
- Development stage
- Unknown
- Lead developer
- Lepu Biopharma
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
This neoadjuvant chemo-immunotherapy regimen is a multimodal treatment approach being investigated by Tang-Du Hospital for the treatment of resectable locally advanced gastroesophageal junction (GEJ) adenocarcinoma. The regimen combines **pucotenlimab** (HX008), a humanized IgG4 monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor to restore anti-tumor immune responses, with a cytotoxic chemotherapy backbone. This backbone consists of **nab-paclitaxel** (an albumin-bound nanoparticle formulation of paclitaxel that stabilizes microtubules), **tegafur** (an oral fluoropyrimidine antimetabolite that inhibits thymidylate synthase), and **carboplatin** (a platinum-based agent that induces DNA alkylation and cross-linking). The combination is administered prior to surgery to reduce tumor volume, eliminate micrometastases, and improve the feasibility of radical resection in patients with cT2N+M0 or cT3-4bNxM0 GEJ tumors.
- Brand names
- PuyoudaoAbraxaneParaplatin
- Other names
- neoadjuvant chemo-immunotherapy-Tang-Du Hospital-gastroesophageal junction adenocarcinomaPucotenlimab + Nab-Paclitaxel + Tegafur + Carboplatin
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on pucotenlimab + nab-paclitaxel + tegafur + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pucotenlimab + nab-paclitaxel + tegafur + carboplatin.